APOE4 Gene Actively Damages Brain Vessels in Alzheimer's, Mechanism Shown to Be Reversible by Blocking TGF-β Signaling

The Alzheimer's research field remains sharply divided over the root cause of the disease's devastating progression. The dominant amyloid camp argues that toxic protein aggregates are the primary engine of neurodegeneration, choking off neuronal function and triggering secondary vascular damage. Conversely, vascular researchers contend that failing blood vessels are the first domino to fall, arguing that a compromised blood-brain barrier traps proteins that would otherwise be cleared. Now, a study published on September 24, 2026, in the journal Cell bridges that divide, demonstrating that the APOE4 gene—the strongest genetic risk factor for Alzheimer's—actively orchestrates both processes simultaneously by transforming the very cells meant to protect the brain's circulation.[1][4]

Researchers at the Icahn School of Medicine at Mount Sinai mapped the single-cell transcriptomics of the human brain's vasculature to understand how the APOE4 variant—which is present in roughly 15 to 25 percent of the general population but found in up to 60 percent of people with late-onset Alzheimer's—exerts its damage. The variant increases Alzheimer's risk by 2 to 3 times in heterozygotes and up to 15-fold in those carrying 2 copies. They discovered that in APOE4 carriers, pericytes—the mural cells that wrap around the brain's estimated 400 miles of capillaries to regulate blood flow—undergo a pathological transdifferentiation.[1][4][6]

Instead of supporting the microvasculature, these pericytes morph into myofibroblast-like cells, effectively becoming scar-producing tissue. This pericyte-to-myofibroblast transition has a devastating downstream effect on the brain's waste clearance systems. The transformed cells begin secreting large amounts of fibronectin, an extracellular matrix protein. As fibronectin builds up, it acts like a biological glue, causing amyloid proteins to stick to the blood vessels rather than being flushed out of the brain.[4][5][6]

"We show that APOE4 converts blood-vessel support cells into scar-producing cells, causing amyloid or abnormal protein buildup to accumulate around the brain's vessels," explained Braxton R. Schuldt, an MD/PhD candidate in the Blanchard Laboratory at Mount Sinai and first author of the study. The breakthrough lies in identifying the chemical signal driving this transformation: elevated transforming growth factor beta (TGF-β) signaling.[1][2]

By applying chemical and genetic inhibitors to block the TGF-β pathway in 3-dimensional stem cell-derived human brain models—dubbed "miBrains"—the research team successfully halted the cellular transition. The intervention did not merely slow the damage; it actively reversed it, restoring the pericyte coverage along the microvasculature to the healthy baseline levels seen in APOE3 carriers. Consequently, vascular fibrosis decreased, and the amyloid accumulation clinging to the blood vessels was cleared.[1][3][4]

"Through our experiments, we were able to block this protein buildup process, revealing possible new therapeutic treatment options and strategies for protecting the brain's circulation in people at high genetic risk for Alzheimer's disease," Schuldt noted. The findings fundamentally reframe how APOE4 exerts its risk, shifting the focus from a passive loss of function to an active, targetable mechanism of vascular destruction.[1][6]

A parallel study published the same day by the Mount Sinai team revealed a second mechanism by which APOE4 paralyzes waste disposal. The gene causes abnormal cholesterol accumulation in astrocytes, another type of support cell, paralyzing their lysosomal waste-disposal systems. This lipid dysregulation allows toxic alpha-synuclein proteins to aggregate and spread to neurons. Together, the two studies map a comprehensive blueprint of how APOE4 systematically dismantles the brain's infrastructure.[1][3]

The development of the cryopreserved miBrain models also accelerates future research into these pathways. Dr. Louise Mesentier-Louro, Assistant Professor of Neuroscience at Mount Sinai and first author of the astrocyte study, emphasized the technological leap. "A key advance of our technology is that miBrains with predefined cellular compositions and disease-related factors can be cryopreserved," she said, noting that this capability improves the reproducibility and scalability of complex disease modeling.[1]

The next hurdle will be translating these TGF-β inhibitors—some of which are already explored in oncology and systemic fibrotic diseases—into safe, brain-penetrant treatments for Alzheimer's patients. Dr. Joel Blanchard, who led the research, emphasized that the miBrain platform will enable personalized studies into how neurodegenerative diseases develop and how specific patients might respond to targeted therapies. By pinpointing the TGF-β pathway, the Mount Sinai team has provided a concrete target that links genetic risk directly to the cerebrovascular pathology observed in patients, offering a tangible path toward repairing the brain's blood vessels.[1][2][6]